As the pharma industry stands firm in its commitment to advance the sector to fight Covid-19, news has emerged from the European Commission who intend to streamline the development of therapies using genetically modified organisms to treat Covid-19. The governing body claims this proposal could have positive effects on mitigating burdensome requirements for gene therapy clinical trials in the future.
In this light, Pharma IQ’s weekly round-up focuses on advancing therapies and clinical trials to combat Covid-19.